AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21346609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18977549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk prepared with Lactobacillus GG (LGG) and L. gasseri TMC0356
Number of subjects: 40
Study 18977549 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 40
Study 18977549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk prepared with Lactobacillus GG (LGG)
Number of subjects: 40
Study 18977549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk prepared with L. gasseri TMC0356
Number of subjects: 40
Study 17501728 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS training for teachers (2-day workshop + 6 half-day sessions over 5 months)
Number of subjects: 84
Study 17501728 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed treatment, no treatment)
Number of subjects: 84
Study 15675430 — intervention group
Group type: EXPERIMENTAL
Intervention: Laying the patient on the paretic side
Number of subjects: 10
Study 15675430 — intervention group
Group type: COMPARATOR
Intervention: Laying the patient on the non-paretic side
Number of subjects: 10
Study 12208675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mist (humidified oxygen)
Number of subjects: 71
Study 12208675 — intervention group
Group type: COMPARATOR
Intervention: No mist
Number of subjects: 71
Study 9658726 — intervention group
Group type: EXPERIMENTAL
Intervention: R-1 (CBDCA 300 mg/m2/d on days 1-4, HIDAC 1 g/m2/bd on days 1-5, mitoxantrone/idarubicin 12/6 mg/m2/d on days 1-3)
Number of subjects: 29
Study 9658726 — intervention group
Group type: EXPERIMENTAL
Intervention: R-2 (CBDCA and G-CSF as above, HIDAC on alternate days, mitoxantrone/idarubicin 8/5 mg/m2/dose)
Number of subjects: 29
Study 9658726 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (complete and partial)
Number of subjects: 29
Study 9658726 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 29
Study 7980831 — intervention group
Group type: EXPERIMENTAL
Intervention: Response options for frequency of alcohol use items in a self‐administered microcomputer interview
Number of subjects: 296
Study 7980831 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of presentation of close‐ended response options
Number of subjects: 296
Study 7980831 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative placement of alcohol use items in the questionnaire
Number of subjects: 296
Study 2588564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific intralymphatic immunotherapy (autologous, cryopreserved, irradiated tumor cells)
Number of subjects: 32
Study 2588564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (300 mg per m2) administered 3 days before the autologous cell vaccine
Number of subjects: 32
Study 2588564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor cells treated with cholesteryl hemisuccinate before irradiation
Number of subjects: 32
Study 2588564 — intervention group
Group type: EXPERIMENTAL
Intervention: Active specific intralymphatic immunotherapy
Number of subjects: 32
Study 1138671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of 2,200 mg of phosphorus and 2,400 mg of calcium
Number of subjects: 29
Study 1138671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1138671 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of vitamin D
Number of subjects: 29
Study 31858835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition Training (IT) group, received training based on a hybrid flanker Go/No-go task, 4 consecutive daily training sessions of 20 minutes each.
Number of subjects: 0
Study 31858835 — intervention group
Group type: COMPARATOR
Intervention: Noninhibition-based (episodic memory; EM) training group.
Number of subjects: 0
Study 31858835 — intervention group
Group type: COMPARATOR
Intervention: No-Training (NT) group, control for test-retest effects.
Number of subjects: 0
Study 30130323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐BM allogeneic islet transplantation (n = 3)
Number of subjects: 13
Study 30130323 — intervention group
Group type: COMPARATOR
Intervention: Islets in the liver (n = 6)
Number of subjects: 13
Study 28041830 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase HCG support (single mid-luteal HCG injection)
Number of subjects: 98
Study 28041830 — intervention group
Group type: COMPARATOR
Intervention: No HCG support
Number of subjects: 98
Study 25934458 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐times‐per-week, 60‐minute structured exercise program for 8 weeks (24 sessions)
Number of subjects: 135
Study 25934458 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 135
Study 24283136 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray vaccination with Poulvac E. coli (aroA-deficient mutant strain)
Number of subjects: 0
Study 24283136 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous use of vaccine with antibiotic ceftiofur sodium
Number of subjects: 0
Study 24283136 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray vaccination
Number of subjects: 0
Study 21150784 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase (0.5 mg/kg weekly for 2 years)
Number of subjects: 94
Study 18645347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention and combination therapy with metformin and glimepiride
Number of subjects: 189
Study 18645347 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple oral therapy (glimepiride + metformin + rosiglitazone)
Number of subjects: 189
Study 18645347 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 189
Study 18645347 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin-requiring group
Number of subjects: 189
Study 18645347 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-requiring group
Number of subjects: 189
Study 18645347 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin-requiring patients
Number of subjects: 189
Study 18645347 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-requiring patients
Number of subjects: 189
Study 17767120 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint gel
Number of subjects: 216
Study 17767120 — intervention group
Group type: COMPARATOR
Intervention: Lanolin ointment
Number of subjects: 216
Study 17767120 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 216
Study 15586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 81
Study 15586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Screws (S)
Number of subjects: 81
Study 15586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegs (P)
Number of subjects: 81
Study 15586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Press-fit technique only (PF)
Number of subjects: 81
Study 15586331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylene oxide-sterilized polyethylene liner
Number of subjects: 81
Study 11548842 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (4 cycles of docetaxel 75 mg/m2 and doxorubicin 50 mg/m2)
Number of subjects: 101
Study 9257210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal opioid (10 micrograms/kg morphine and 25 micrograms fentanyl)
Number of subjects: 21
Study 9257210 — intervention group
Group type: COMPARATOR
Intervention: Control (no intrathecal opioid, received 25 to 50 micrograms/kg fentanyl and 0.05 to 0.1 mg/kg midazolam intraoperatively)
Number of subjects: 21
Study 8279691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammock position (30 degrees trunk elevation with 30 degrees leg elevation)
Number of subjects: 30
Study 8279691 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position (supine)
Number of subjects: 30
Study 3495151 — intervention group
Group type: EXPERIMENTAL
Intervention: RF power level 0.2 W/kg
Number of subjects: 27
Study 3495151 — intervention group
Group type: EXPERIMENTAL
Intervention: RF power level 0.8 W/kg
Number of subjects: 27
Study 3495151 — intervention group
Group type: COMPARATOR
Intervention: RF power level 0 W/kg
Number of subjects: 27
Study 3495151 — intervention group
Group type: COMPARATOR
Intervention: RF power level 0.2 W/kg (head scans)
Number of subjects: 27
Study 3495151 — intervention group
Group type: COMPARATOR
Intervention: RF power level 0.8 W/kg (head scans)
Number of subjects: 27
Study 30514319 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of dihydrotestosterone in males
Number of subjects: 285
Study 30514319 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of 17-OH-progesterone in males
Number of subjects: 285
Study 30514319 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels in males
Number of subjects: 285
Study 27035604 — intervention group
Group type: EXPERIMENTAL
Intervention: SPS‐DECTA
Number of subjects: 80
Study 27035604 — intervention group
Group type: COMPARATOR
Intervention: DECTA
Number of subjects: 80
Study 24623508 — intervention group
Group type: COMPARATOR
Intervention: M1-M1 tDCS
Number of subjects: 0
Study 24623508 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-M1 tDCS
Number of subjects: 0
Study 24623508 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 24623508 — intervention group
Group type: EXPERIMENTAL
Intervention: All sessions (M1-M1, PM-M1, Sham)
Number of subjects: 0
Study 24624878 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal savda munziq (ASMq) at 0.1-1.0 mg/ml
Number of subjects: 6
Study 24624878 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-Fu)
Number of subjects: 6
Study 24624878 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 6
Study 20798196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus Letrozole (L + Let)
Number of subjects: 219
Study 20798196 — intervention group
Group type: COMPARATOR
Intervention: Letrozole plus placebo (Let)
Number of subjects: 219
Study 17543540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ownership of objects (self-owned vs. other-owned)
Number of subjects: 0
Study 17543540 — intervention group
Group type: COMPARATOR
Intervention: Moving items (acting on items)
Number of subjects: 0
Study 15721728 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 15721728 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 12972100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous platelet glycoprotein IIb/IIIa antagonists
Number of subjects: 20186
Study 11910657 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal estradiol 50 micrograms/day and oral medroxyprogesterone acetate 10 mg/day during the last 12 days of the month
Number of subjects: 100
Study 11910657 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate - oral clodronate 400 mg/day for 1 month out of every 3 months
Number of subjects: 100
Study 11910657 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin - nasal spray 100 IU/day
Number of subjects: 100
Study 11910657 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate plus Calcitonin - oral clodronate 400 mg/day for 1 month out of every 3 months plus calcitonin nasal spray 100 IU/day
Number of subjects: 100
Study 9399465 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA alone
Number of subjects: 34
Study 9399465 — intervention group
Group type: COMPARATOR
Intervention: PTA with Wallstent
Number of subjects: 34
Study 8186713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low dosage schedule of Prednisolone at 0.75 mg kg‐1 day‐1 for 10 days at the beginning of each calendar month
Number of subjects: 32
Study 3531731 — intervention group
Group type: EXPERIMENTAL
Intervention: New membrane oxygenator (LPM 50)
Number of subjects: 30
Study 3531731 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator
Number of subjects: 30
Study 28361171 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite 2% gel toothpaste fluoride free
Number of subjects: 105
Study 28361171 — intervention group
Group type: COMPARATOR
Intervention: fluoride gel toothpaste
Number of subjects: 105
Study 28361171 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 26910438 — intervention group
Group type: EXPERIMENTAL
Intervention: Music with noise-canceling headphones (NCHs) during SWL
Number of subjects: 89
Study 26910438 — intervention group
Group type: EXPERIMENTAL
Intervention: Music with non-noise-canceling headphones (non-NCHs) during SWL
Number of subjects: 89
Study 26910438 — intervention group
Group type: COMPARATOR
Intervention: No headphones and music (Control group)
Number of subjects: 89
Study 24965700 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 269
Study 24965700 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 269
Study 24965700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 24965700 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 269
Study 22672941 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 14
Study 22672941 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study 22672941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRT and CON
Number of subjects: 14
Study 21252486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia therapy
Number of subjects: 0
Study 21252486 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 0
Study 18352982 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal imagery training for 72 minutes over six weeks
Number of subjects: 0
Study 18352982 — intervention group
Group type: COMPARATOR
Intervention: Regular workouts (control group)
Number of subjects: 0
Study 15544421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acids mixture without tryptophan)
Number of subjects: 20
Study 15544421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same mixture with tryptophan)
Number of subjects: 20
Study 11877686 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus aspirin therapy (WASA)
Number of subjects: 831
Study 11877686 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy alone (ASA)
Number of subjects: 831
Study 9561883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive practices (diet and drugs)
Number of subjects: 3863
Study 9561883 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of AMI triggers
Number of subjects: 3863
Study 9561883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Number of subjects: 3863
Study 9561883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive practices usage
Number of subjects: 3863
Study 7625118 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms rgp160 vaccine adjuvanted in alum and deoxycholate
Number of subjects: 10
Study 7625118 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms rgp160 immunization
Number of subjects: 10
Study 3395106 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g every 6 h
Number of subjects: 12
Study 3395106 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g every 8 h
Number of subjects: 12
Study 29268939 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise group (SG)
Number of subjects: 20
Study 29268939 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive group (CG)
Number of subjects: 20
Study 28595862 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 627
Study 28595862 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 627
Study 26122230 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution magnetic resonance angiography (MRA)
Number of subjects: 200
Study 23830165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic foot pumps (IPF)
Number of subjects: 24
Study 23830165 — intervention group
Group type: COMPARATOR
Intervention: Control (no IPF)
Number of subjects: 24
Study 20652275 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (150 mg, orally, once daily for 1 month)
Number of subjects: 24
Study 20652275 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, same duration as intervention)
Number of subjects: 24
Study 18988907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1489
Study 18988907 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1489
Study 17074343 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular samples pooled for cDNA microarray analysis
Number of subjects: 24
Study 17074343 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcription‐polymerase chain reaction (RT‐PCR)
Number of subjects: 24
Study 15014412 — intervention group
Group type: COMPARATOR
Intervention: Halogen light curing for 20 seconds
Number of subjects: 83
Study 15014412 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc light curing for 5 seconds
Number of subjects: 83
Study 11337296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine injected lateral to the seminal vesicles
Number of subjects: 0
Study 11337296 — intervention group
Group type: COMPARATOR
Intervention: Sterile normal saline injected lateral to the seminal vesicles
Number of subjects: 0
Study 9075853 — intervention group
Group type: COMPARATOR
Intervention: CsA (n=50)
Number of subjects: 101
Study 9075853 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-ME (n=51)
Number of subjects: 101
Study 7950906 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH measured after the marathon
Number of subjects: 7
Study 7950906 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH measured after recovery
Number of subjects: 7
Study 7950906 — intervention group
Group type: COMPARATOR
Intervention: hGH measured in athletes vs controls after the marathon
Number of subjects: 7
Study 7950906 — intervention group
Group type: COMPARATOR
Intervention: IGF-I measured in athletes and controls
Number of subjects: 7
Study 3839111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazmegrel
Number of subjects: 20
Study 3839111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27466610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantawid conditional cash transfer program
Number of subjects: 485
Study 27466610 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 485
Study 24708702 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated abdominal amnioinfusion
Number of subjects: 56
Study 24708702 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 56
Study 22409782 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 30)
Number of subjects: 60
Study 22409782 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study 19996310 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (12 wk of exercise without diet restriction)
Number of subjects: 79
Study 19996310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (8 wk of very low energy diet 600 kcal/d followed by 4 wk with a weight maintenance diet)
Number of subjects: 79
Study 19996310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet and exercise (DEX; 8 wk very low energy diet 800 kcal/d followed by 4 wk weight maintenance diet combined with exercise throughout the 12 wk)
Number of subjects: 79
Study 18542839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 800
Study 18542839 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 800
Study 17457441 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin daily (n=72)
Number of subjects: 145
Study 17457441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=73)
Number of subjects: 145
Study 15520068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cisplatin, interferon, doxorubicin and fluorouracil (PIAF)
Number of subjects: 102
Study 15520068 — intervention group
Group type: COMPARATOR
Intervention: Single-agent doxorubicin
Number of subjects: 102
Study 10866893 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored Anesthesia Care (MAC) with propofol 50-100 microg/kg/min IV and remifentanil for pain control.
Number of subjects: 100
Study 10866893 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) with propofol 1.5 mg/kg IV, remifentanil 0.125 microg/kg IV, maintained with desflurane (2%-4%) and nitrous oxide (60%).
Number of subjects: 100
Study 9505980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 0.5 mg inhaled with and without oral charcoal
Number of subjects: 0
Study 9505980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide 1 mg, 2 mg, and 3 mg inhaled with concomitant charcoal
Number of subjects: 0
Study 9505980 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 9505980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (all doses)
Number of subjects: 0
Study 9505980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide administered at 10 PM
Number of subjects: 0
Study 1540717 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 20
Study 1540717 — intervention group
Group type: COMPARATOR
Intervention: Aortography
Number of subjects: 20
Study 2860041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 to 800 mg once daily for 12 weeks)
Number of subjects: 45
Study 2860041 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 to 320 mg twice daily for 12 weeks)
Number of subjects: 45
Study 2860041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 45
Study 2860041 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 45
Study 2860041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 45
Study 30285519 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepTrackTXT2 intervention (behavioral, non-pharmacological), additional text messages with recommendations for fatigue mitigation, weekly text messages promoting sleep.
Number of subjects: 100
Study 30285519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 100